Anthem Bioscienc

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0CZ201020
  • NSEID: ANTHEM
  • BSEID: 544449
INR
784.20
-0.45 (-0.06%)
BSENSE

May 11

BSE+NSE Vol: 7.61 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

7.61 lacs (103.93%) Volume

Shareholding (Mar 2026)

FII

1.28%

Held by 37 FIIs

DII

0.50%

Held by 26 DIIs

Promoter

74.68%

Is Anthem Bioscienc overvalued or undervalued?

01-Sep-2025

As of August 29, 2025, Anthem Bioscienc is considered very expensive with a PE ratio of 90.82 and other high valuation metrics, indicating it is overvalued compared to peers, despite a recent positive return of 4.51%.

As of 29 August 2025, the valuation grade for Anthem Bioscienc has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 90.82, a Price to Book Value of 18.59, and an EV to EBITDA ratio of 65.82. These ratios are considerably higher than its peers, such as Sun Pharma with a PE of 33.34 and Divi's Lab at 70.28, both of which are categorized as expensive or very expensive.<BR><BR>In comparison to other companies in the pharmaceuticals and biotechnology sector, Anthem Bioscienc's high valuation metrics suggest that investors are paying a premium for its stock. The PEG ratio is notably at 0.00, which raises concerns about growth expectations not being met. While the stock has shown a positive return of 4.51% over the past month compared to a decline in the Sensex, the overall valuation still points to an overvaluation scenario.

View full answer

How has been the historical performance of Anthem Bioscienc?

09-Nov-2025

Anthem Bioscienc experienced significant growth from March 2024 to March 2025, with net sales rising to 1,844.55 Cr and profit after tax increasing to 451.26 Cr. Key metrics such as operating profit and cash flow also improved, reflecting strong financial performance.

Answer:<BR>The historical performance of Anthem Bioscienc shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Anthem Bioscienc reported net sales of 1,844.55 Cr in March 2025, an increase from 1,419.37 Cr in March 2024. The total operating income also rose to 1,844.55 Cr from 1,419.37 Cr, while total expenditure increased to 1,173.72 Cr from 914.40 Cr. This led to an operating profit (PBDIT) of 756.56 Cr, up from 568.67 Cr the previous year. Profit before tax reached 656.87 Cr, compared to 477.32 Cr in the prior year, resulting in a profit after tax of 451.26 Cr, which was higher than 367.31 Cr in March 2024. The earnings per share increased to 8.07 from 6.57, and the operating profit margin improved slightly to 36.37% from 35.58%. On the balance sheet, total assets grew to 2,789.64 Cr from 2,356.72 Cr, while total liabilities also increased to 2,789.64 Cr from 2,356.72 Cr. The cash flow from operating activities saw a notable rise to 418.00 Cr from 140.00 Cr, contributing to a net cash inflow of 132.00 Cr, reversing the outflow of 158.00 Cr in the previous year. Overall, Anthem Bioscienc demonstrated robust growth in sales, profits, and cash flow, indicating a strong financial performance.

View full answer

When is the next results date for Anthem Biosciences Ltd?

28-Jan-2026

The next results date for Anthem Biosciences Ltd is February 5, 2026.

The next results date for Anthem Biosciences Ltd is scheduled for February 5, 2026.

View full answer

Should I buy, sell or hold Anthem Biosciences Ltd?

08-May-2026

Why is Anthem Biosciences Ltd falling/rising?

11-May-2026

As of 10-May, Anthem Biosciences Ltd's stock price is rising to 784.55, with a year-to-date increase of 20.51%. The stock has shown strong performance, outpacing the benchmark Sensex, driven by high management efficiency and growing institutional investment.

As of 10-May, Anthem Biosciences Ltd's stock price is rising, currently at 784.55, reflecting a change of 5.65 (0.73%) upward. The stock has shown strong performance over various periods, with a 3.26% increase over the past week and a significant 13.73% rise over the last month, while the benchmark Sensex has seen a decline of 0.30% in the same timeframe. Year-to-date, the stock has appreciated by 20.51%, contrasting sharply with the Sensex's drop of 9.26%.<BR><BR>Today's performance indicates that the stock has outperformed its sector by 0.75% and has been on a consecutive gain streak for three days, accumulating a total return of 3.09% during this period. The stock reached an intraday high of Rs 804.65, marking a 3.31% increase. Additionally, it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically signals a bullish trend.<BR><BR>Positive factors contributing to this rise include high management efficiency, evidenced by a return on equity (ROE) of 19.93%, and the company being net-debt free. Furthermore, Anthem Biosciences has demonstrated healthy long-term growth, with net sales increasing at an annual rate of 29.80% and operating profit growing at 44.32%. There is also increasing participation from institutional investors, who have raised their stake by 3.87% over the previous quarter, indicating confidence in the company's fundamentals.<BR><BR>Despite some negative results reported in December, including declines in profit before tax and net sales, the overall positive trends in stock performance, management efficiency, and institutional investment are driving the stock price upward.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Negative results in Dec 25

  • PBT LESS OI(Q) At Rs 122.31 cr has Fallen at -24.2% (vs previous 4Q average)
  • NET SALES(Q) At Rs 423.15 cr has Fallen at -18.3% (vs previous 4Q average)
  • PAT(Q) At Rs 110.87 cr has Fallen at -14.1% (vs previous 4Q average)
2

With ROE of 17.7, it has a Very Expensive valuation with a 15.5 Price to Book Value

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 43,260 Cr (Mid Cap)

stock-summary
P/E

88.00

stock-summary
Industry P/E

34

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.34

stock-summary
Return on Equity

17.74%

stock-summary
Price to Book

15.44

Revenue and Profits:
Net Sales:
423 Cr
(Quarterly Results - Dec 2025)
Net Profit:
93 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
13.3%
0%
13.3%
6 Months
15.22%
0%
15.22%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Anthem Bioscienc for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
29.80%
EBIT Growth (5y)
44.32%
EBIT to Interest (avg)
56.77
Debt to EBITDA (avg)
0.16
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.62
Tax Ratio
28.85%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
12.83%
ROCE (avg)
32.59%
ROE (avg)
19.93%

Valuation key factors

Factor
Value
P/E Ratio
88
Industry P/E
34
Price to Book Value
15.47
EV to EBIT
70.65
EV to EBITDA
62.66
EV to Capital Employed
23.02
EV to Sales
23.45
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
32.59%
ROE (Latest)
17.74%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
Bollinger Bands
Bullish
KST
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 27 Schemes (10.12%)

FIIs

Held by 37 FIIs (1.28%)

Promoter with highest holding

Ajay Bhardwaj (42.53%)

Highest Public shareholder

Portsmouth Technologies Llc . (2.74%)

Individual Investors Holdings

9.38%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -24.56% vs 2.64% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -43.50% vs 33.77% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "416.58",
          "val2": "552.23",
          "chgp": "-24.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "163.05",
          "val2": "225.66",
          "chgp": "-27.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.13",
          "val2": "2.23",
          "chgp": "-49.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-24.98",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "112.12",
          "val2": "198.43",
          "chgp": "-43.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "39.14%",
          "val2": "40.86%",
          "chgp": "-1.72%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,090.24",
          "val2": "863.40",
          "chgp": "26.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "421.08",
          "val2": "324.04",
          "chgp": "29.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.84",
          "val2": "5.20",
          "chgp": "-26.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "346.77",
          "val2": "255.63",
          "chgp": "35.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "38.62%",
          "val2": "37.53%",
          "chgp": "1.09%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,506.82",
          "val2": "1,361.66",
          "chgp": "10.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "584.13",
          "val2": "490.89",
          "chgp": "18.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.97",
          "val2": "6.99",
          "chgp": "-28.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-24.98",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "458.89",
          "val2": "383.62",
          "chgp": "19.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "38.77%",
          "val2": "36.05%",
          "chgp": "2.72%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,840.65",
          "val2": "1,417.54",
          "chgp": "29.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "689.01",
          "val2": "504.89",
          "chgp": "36.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "9.09",
          "val2": "9.14",
          "chgp": "-0.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "506.19",
          "val2": "374.78",
          "chgp": "35.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "37.43%",
          "val2": "35.62%",
          "chgp": "1.81%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
416.58
552.23
-24.56%
Operating Profit (PBDIT) excl Other Income
163.05
225.66
-27.75%
Interest
1.13
2.23
-49.33%
Exceptional Items
-24.98
0.00
Standalone Net Profit
112.12
198.43
-43.50%
Operating Profit Margin (Excl OI)
39.14%
40.86%
-1.72%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is -24.56% vs 2.64% in Sep 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Dec 2025 is -43.50% vs 33.77% in Sep 2025

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
1,090.24
863.40
26.27%
Operating Profit (PBDIT) excl Other Income
421.08
324.04
29.95%
Interest
3.84
5.20
-26.15%
Exceptional Items
0.00
0.00
Standalone Net Profit
346.77
255.63
35.65%
Operating Profit Margin (Excl OI)
38.62%
37.53%
1.09%
Values in Rs Cr.
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

Nine Monthly Results Snapshot (Standalone) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
1,506.82
1,361.66
10.66%
Operating Profit (PBDIT) excl Other Income
584.13
490.89
18.99%
Interest
4.97
6.99
-28.90%
Exceptional Items
-24.98
0.00
Standalone Net Profit
458.89
383.62
19.62%
Operating Profit Margin (Excl OI)
38.77%
36.05%
2.72%
Values in Rs Cr.
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

Annual Results Snapshot (Standalone) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
1,840.65
1,417.54
29.85%
Operating Profit (PBDIT) excl Other Income
689.01
504.89
36.47%
Interest
9.09
9.14
-0.55%
Exceptional Items
0.00
0.00
Standalone Net Profit
506.19
374.78
35.06%
Operating Profit Margin (Excl OI)
37.43%
35.62%
1.81%
Values in Rs Cr.
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

stock-summaryCompany CV
About Anthem Biosciences Ltd stock-summary
stock-summary
Anthem Biosciences Ltd
Mid Cap
Pharmaceuticals & Biotechnology
Anthem Biosciences Limited was originally incorporated as "Anthem Biosciences Private Limited", dated June 13, 2006, issued by RoC. Subsequently, Company was converted from a Private Company to a Public Company , followed by the change in name of the Company to "Anthem Biosciences Limited" and a Certificate of Incorporation upon the conversion was issued by RoC on December 10, 2024.
Company Coordinates stock-summary
Icon
No Company Details Available